Compare Ginkgo Bioworks Holdings Inc (DNA) vs Texas Instruments Incorporated (TXN) Price & Performance

Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% today, reflecting ongoing volatility. The stock shows a bullish technical signal with strong moving average support, but fundamentals reveal significant challenges: revenue declined to $170.16M in 2025 with a net loss of $312.76M, and negative cash flow persists. Recent news includes a partnership with TuneLab for AI-driven drug discovery and a $17.5M ARPA-H subcontract for RNA medicine manufacturing, indicating strategic growth initiatives amid financial headwinds.

The outlook remains high-risk due to persistent losses and cash burn, though analyst sentiment is split evenly between buy, hold, and sell. Upside potential hinges on successful commercialization of its platform and cost management, while downside risks include execution missteps and prolonged profitability challenges. Investors should weigh the company's innovative partnerships against its weak financial metrics.

Texas Instruments (TXN) trades at $288.2, down 3.06% today amid a semiconductor sector sell-off. The stock shows strong technical momentum with bullish moving averages and key support at $286. Fundamentally, Q2 2026 EPS beat expectations at $2.14 versus $1.91, driven by data center sales doubling. Revenue growth is accelerating with 2026 projections at $19.5B, while maintaining robust profitability with 31.11% net margins. Recent dividend payments and institutional buying by CalSTRS signal confidence.

Outlook remains positive with 47.7% analyst buy ratings and $325 consensus price target offering 13% upside. Key catalysts include AI-driven data center expansion and industrial recovery. Risks include premium valuation (P/E 43.9) and cyclical semiconductor demand. The earnings recovery trajectory supports continued growth despite near-term volatility.